Bio­Car­dia paus­es en­roll­ment in PhI­II tri­al of heart fail­ure stem cell ther­a­py

Bio­Car­dia has paused en­roll­ment in a piv­otal study of its stem cell ther­a­py for heart fail­ure af­ter an in­de­pen­dent re­view board de­ter­mined the tri­al was not like­ly to suc­ceed.

The Sun­ny­vale, CA-based biotech said Mon­day morn­ing that the da­ta and safe­ty mon­i­tor­ing board (DSMB) re­viewed an in­ter­im read­out of the Phase III tri­al of its stem cell ther­a­py for sys­tolic heart fail­ure. The board de­ter­mined it was “un­like­ly to meet” the pri­ma­ry ef­fi­ca­cy end­point, a com­pos­ite mea­sure of sur­vival, ma­jor car­diac events (such as heart at­tacks) and re­sults from a six-minute walk test at one year.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER